Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending January 2010. The report serves as a notification of transactions involving directors and persons discharging managerial responsibility under the SmithKline Beecham Mid-Term Incentive Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on specific share transactions.
- Transaction Price: $41.48 per Ordinary share ADR.
- Transaction Type: Increase in interests following dividend re-investment.
- Dividend Date: January 7, 2010.
Material Changes
The filing reports an increase in shareholdings for specific individuals due to the re-investment of dividends paid on January 7, 2010. No material changes to the company's financial position or operations are disclosed in this document.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, risks, contingencies, or unusual items. It is a compliance notification pursuant to Disclosure and Transparency Rule 3.1.4R(1)(a).
Investor Verification Points
- Verify the total number of ADRs held by Mr. E J Gray (14.97) and Mr. D J Phelan (453.68) post-transaction.
- Confirm the dividend re-investment mechanism details for the SmithKline Beecham Mid-Term Incentive Plan.
- Check subsequent filings for broader financial performance data, as this 6-K is limited to director transaction notifications.